Clinical trials
HER2-positive Metastatic Breast Cancer clinical trials
Below are recruiting her2-positive metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 169 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07455188Recruiting
Switching targeted therapies for advanced HER2-positive breast cancer
This trial tests whether switching between two targeted therapy combinations can help women with HER2-positive advanced breast cancer that has progressed after previous treatments. It aims to find a new effective option for people who have already tried one or two lines of therapy.
Zhejiang, HangzhouAges 18 years+ - NCT07413939RecruitingPhase 2/Phase 3
Study of RO7771950 vs tucatinib for HER2-positive breast cancer
This trial tests a new drug, RO7771950, against another drug called tucatinib. Both are given with standard chemotherapy to see which works better for advanced breast cancer that is HER2-positive. People with brain metastases may join.
Huntsville, AlabamaAges 18 years+ - NCT07407920RecruitingPhase 2
Optimizing treatment for early HER2+ and triple-negative breast cancer
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
Houston, TexasAges 18 years+ - NCT07402473RecruitingPhase 2
Optimizing treatment before surgery for HER2-positive breast cancer
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
Elizabeth, New JerseyAges 18–90 - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05918328RecruitingPhase 2
Testing two medicines before surgery for HER2-positive breast cancer
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
Zhengzhou, HenanAges 18–65 - NCT06035679Recruiting
Combination therapy before surgery for HER2-positive breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for HER2-positive breast cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
Fuzhou, FujianAges 18–75 - NCT07299825RecruitingPhase 2
Study of A166 for advanced HER2-positive breast cancer
This trial tests a new drug called A166 for people with HER2-positive breast cancer that has spread or can't be removed. It is for those who have already tried up to five treatments, including a specific type of HER2 antibody-drug conjugate.
Zhenzhou, HenanAges 18–75 - NCT07292571Enrolling by invitationPhase 2
Tracing breast cancer HER2 with a special scan
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
TomskAges 18–80 - NCT07294508RecruitingPhase 2/Phase 3
Testing a new drug combo for HER2-positive advanced breast cancer
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07281001Recruiting
Trastuzumab deruxtecan study for breast cancer patients
This study looks at how well the drug trastuzumab deruxtecan works in women with breast cancer that has spread. It is for patients who have already taken this drug.
MoscowAges 18–80 - NCT07285382RecruitingPhase 2
Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
Dalian, LiaoningAges 18–75 - NCT06846437RecruitingPhase 3
New drug JSKN003 vs. Kadcyla for HER2-positive advanced breast cancer
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
ShanghaiAges 18 years+ - NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT07233928Recruiting
Breast cancer protein study in different subtypes
This trial takes a close look at the proteins inside breast cancer cells, using samples from people with different subtypes. It aims to better understand how each type behaves, which could help guide future treatments.
ToulouseAges 18 years+ - NCT05406635Recruiting
Imaging vs blood tests to guide heart-safe HER2 treatment
This trial compares whether special heart imaging or blood tests better helps monitor heart safety while you receive HER2-targeted therapy (like trastuzumab, with or without pertuzumab) plus chemotherapy. It may help doctors catch early heart stress and choose the safest treatment plan for you.
AalborgAges 18–90 - NCT07220135RecruitingPhase 2
Comparing two drug combos before surgery for HER2+ breast cancer
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Fairway, KansasAges 18 years+ - NCT06837792RecruitingPhase 2
T-DXd vs hormone therapy for HER2-low advanced breast cancer
This trial compares a targeted antibody-drug conjugate called T-DXd against standard hormone therapy for women with HR+, HER2-low advanced breast cancer that has progressed after first-line endocrine therapy plus a CDK4/6 inhibitor. It aims to see if T-DXd works better than continuing hormone therapy alone.
SeoulAges 19 years+ - NCT07180082RecruitingPhase 2
Pyrotinib for HER2-positive advanced breast cancer
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
ShanghaiAges 18 years+ - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07166185Recruiting
Targeted therapy before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (trastuzumab and pertuzumab) given as a shot under the skin before surgery for women with a specific type of breast cancer called HER2-positive. The goal is to see if this treatment works well for women in Algeria.
BlidaAges 19 years+ - NCT07162675Recruiting
Step count and treatment response in breast cancer patients
This study looks at how your daily step count, measured by a smartwatch, relates to how well your breast cancer responds to treatment before surgery. It may help show if being more active during chemotherapy leads to better outcomes.
Ankara, YenimahalleAges 18 years+
Hear when a new HER2-positive Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-positive metastatic breast cancer?
- Yes. Clin2 currently lists 169 recruiting her2-positive metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-positive metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-positive metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- HER2-positive Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HER2-positive Advanced Breast Cancer
- HR-positive, HER2-negative Advanced Breast Cancer
- HER2-positive Early Breast Cancer
- HR Positive/HER2 Low Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.